Pletal

(cilostazol)

ApprovedSmall molecule

Cilostazol is used to improve walking distance in people with a painful leg condition called intermittent claudication, which is caused by poor blood circulation in the legs.[2] Pletal is currently approved and in use across 43 indications[4].[1]

Pletal is one of 909 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

113

Total Trials

Active Trials

908

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseApproved

Hepatic SteatosisApproved

ContraceptionApproved

Cardiovascular DiseaseApproved

Cerebral IschemiaActive, not recruiting

Cerebral Small Vessel DiseaseApproved

Migraine DisorderActive, not recruiting

Cognitive ImpairmentActive, not recruiting

StrokeApproved

Peripheral NeuropathyActive, not recruiting

Coronary Artery DiseaseApproved

Approved

Hepatic SteatosisApproved

Approved

ContraceptionApproved

Approved

Cardiovascular DiseaseApproved

Approved

Cerebral IschemiaApproved

Active, not recruiting

Cerebral Small Vessel DiseaseApproved

Approved

Migraine DisorderPreclinical

Active, not recruiting

Cognitive ImpairmentPhase 2

Active, not recruiting

StrokeApproved

Approved

Peripheral NeuropathyPhase 1/Phase 2

Active, not recruiting

Showing 10 of 40 indications

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Pletal

Otsuka

Approved

2 2

Actemra

Simponi

19 4

Remicade

OOrganon and Co

Preclinical

43 5

Arcoxia

Novartis

Preclinical

4 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Cataflam

Novartis

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 9

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Certolizumab

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Alcoholic Fatty Liver Disease

NCT07238985

Q4 2027

Post-ApprovalNot yet recruiting

Cerebral Small Vessel Disease

NCT07180472

Post-ApprovalRecruiting

Clopidogrel

NCT06402747

Phase 2Recruiting

Neuropathy

NCT06492070

Phase 3Not yet recruiting

Stroke

NCT06919835

Q1 2028

Post-ApprovalRecruiting

Atherosclerosis

NCT06757764

Clinical

Trials by Indication[1]

Stroke10 trials

Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds

Recruiting·ZZhejiang Provincial People's Hospital·Phase 3·NCT06530537·848 enrolled

Cilostazol Stroke Prevention Study for Antiplatelet Combination

Completed·JJapan Cardiovascular Research Foundation·Phase 4·NCT01995370·1,884 enrolled

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591377·900 enrolled

Show 7 more trials

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591351·870 enrolled

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591390·900 enrolled

Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591299·870 enrolled

CiLostAzol for pReventIon of Recurrent sTroke in Africa

Not yet recruiting·NNorthern California Institute of Research and Education·Phase 3·NCT06919835·1,100 enrolled

Cilostazol for Prevention of Recurrent Stroke Trial

Not yet recruiting·SStanford University·Phase 3·NCT07174414·2,000 enrolled

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Completed· Otsuka logo

Otsuka·Phase 4·NCT00234065·2,800 enrolled

Cilostazol and Aspirin in Stroke and TIA

Completed·IIncheon St.Mary's Hospital·Phase 4·NCT06522113·378 enrolled

Ischemic stroke8 trials

Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 4·NCT00272454·468 enrolled

PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study

Unknown status·—·Phase 4·NCT02483169·800 enrolled

PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage

Unknown status·—·Phase 4·NCT01013532·1,600 enrolled

Show 5 more trials

Clopidogrel Versus Cilostazol in Ischemic Stroke

Completed·KKafrelsheikh University·Phase 3·NCT06242132·870 enrolled

Ticagrelor Versus Cilostazol in Ischemic Stroke

Recruiting·KKafrelsheikh University·Phase 3·NCT06561867·900 enrolled

Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06196047·900 enrolled

Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke

Completed·KKafrelsheikh University·Phase 3·NCT06242145·580 enrolled

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Recruiting·KKafrelsheikh University·Phase 3·NCT06202755·580 enrolled

Fasting Conditions6 trials

A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions

Completed· Otsuka logo

Otsuka·Phase 1·NCT00773630·44 enrolled

Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions

Completed·RRoxane Laboratories·N/A·NCT00602407·36 enrolled

Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions

Completed·RRoxane Laboratories·N/A·NCT00602173·32 enrolled

Show 3 more trials

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

Completed· Novartis logo

Novartis·Phase 1·NCT00881231·26 enrolled

Cilostazol 50 mg Tablets Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00839930·30 enrolled

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00838630·36 enrolled

Headache5 trials

The Headache Inducing Effects of Cilostazol on Migraine Patients

Completed·DDanish Headache Center·N/A·NCT01841827·14 enrolled

The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

Unknown status·DDanish Headache Center·N/A·NCT04452929·72 enrolled

The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache

Completed·DDanish Headache Center·N/A·NCT03422796·30 enrolled

Show 2 more trials

The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache

Completed·DDanish Headache Center·N/A·NCT02486276·30 enrolled

Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache

Unknown status·DDanish Headache Center·N/A·NCT05595993·21 enrolled

MPA5 trials

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Completed·GGenovate Biotechnology Co., Ltd.,·Phase 1·NCT05466734·25 enrolled

Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Completed·GGenovate Biotechnology Co., Ltd.,·Phase 1·NCT03864666·28 enrolled

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

Completed·GGenovate Biotechnology Co., Ltd.,·Phase 1·NCT06167265·40 enrolled

Show 2 more trials

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Completed·GGenovate Biotechnology Co., Ltd.,·Phase 1·NCT03480321·21 enrolled

Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers

Terminated·GGenovate Biotechnology Co., Ltd.,·Phase 1·NCT05191862·19 enrolled

56 more indications

Trial4 trials

Lacunar Intervention Trial 1 (LACI-1)

Completed·UUniversity of Edinburgh·Phase 2·NCT02481323·57 enrolled

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II

Completed·—·Phase 4·NCT00130039·457 enrolled

Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial

Completed·UUniversity of Oxford·Phase 2·NCT03855332·75 enrolled

Show 1 more trial

LACunar Intervention (LACI-2) Trial-2

Completed·UUniversity of Edinburgh·Phase 2/3·NCT03451591·363 enrolled

Atherosclerosis3 trials

Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT03248401·50 enrolled

Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker

Completed· Otsuka logo

Otsuka·Phase 4·NCT00823849·200 enrolled

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Recruiting·—·Phase 4·NCT06757764·2,340 enrolled

Dual Antiplatelet Therapy3 trials

Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation

Completed·YYonsei University·Phase 4·NCT01192724·630 enrolled

Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent

Completed·CCardioVascular Research Foundation, Korea·Phase 4·NCT00589927·486 enrolled

Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation

Completed·SShenyang Northern Hospital·Phase 4·NCT00404716

Cognitive impairment2 trials

Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)

Unknown status·HHuashan Hospital·N/A·NCT01872858·200 enrolled

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

Completed·NNational Cerebral and Cardiovascular Center, Japan·Phase 2·NCT02491268·166 enrolled

Cerebral Small Vessel Disease2 trials

Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

Unknown status·IInha University Hospital·Phase 4·NCT01932203·255 enrolled

Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol

Not yet recruiting·FFirst Affiliated Hospital of Chengdu Medical College·Phase 4·NCT07180472·632 enrolled

Peripheral Arterial Disease2 trials

The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)

Completed·—·Phase 4·NCT01188824·801 enrolled

Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

Completed· Sanofi logo

Sanofi·Phase 2·NCT00443287·553 enrolled

Clopidogrel2 trials

Clopidogrel Versus Cilostazol on Vessels

Recruiting·SSeoul National University Bundang Hospital·Phase 4·NCT06402747·120 enrolled

Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients

Completed·—·N/A·NCT01779401·1,078 enrolled

ART2 trials

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Completed·UUniversity of Ioannina·Phase 4·NCT02983214·826 enrolled

Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)

Completed·NNational Cheng-Kung University Hospital·Phase 4·NCT01952756·44 enrolled

Migraine2 trials

Induction of Migraine Aura With Cilostazol

Completed·HHerlev Hospital·Phase 1·NCT02253004·16 enrolled

Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

Completed·DDanish Headache Center·N/A·NCT02549898·34 enrolled

Treatment2 trials

Sufficient Treatment of Peripheral Intervention by Cilostazol

Unknown status·—·Phase 4·NCT00912756·200 enrolled

Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)

Terminated·SSeung-Jung Park·Phase 4·NCT01346865·402 enrolled

Rheumatoid Arthritis2 trials

Cilostazol and Methotrexate in Rheumatoid Arthritis

Recruiting·TTanta University·Phase 3·NCT05594680·70 enrolled

The Effect of Cilostazol on Rheumatoid Arthritis Patients

Completed·—·Phase 2/3·NCT05671497·70 enrolled

Interaction2 trials

Cilostazol-Simvastatin Drug Interaction Study

Unknown status·—·Phase 1·NCT02431013·20 enrolled

Pharmacodynamic Drug Interaction Between Cilostazol and Statins

Completed·SSamsung Medical Center·Phase 1·NCT01870466·63 enrolled

Subarachnoid Hemorrhage2 trials

Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage

Not yet recruiting·—·Phase 3·NCT07144956·630 enrolled

Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

Terminated·HHenry Ford Health System·Phase 4·NCT04148105·19 enrolled

TED2 trials

Fasted Bioavailability Study of Cilostazol Tablets, 100 mg

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00684762·32 enrolled

Fasted Bioavailability Study of Cilostazol Tablets, 50mg

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00685802·32 enrolled

Efficacy and Safety1 trial

A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina

Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 3·NCT02087007·100 enrolled

Parkinson1 trial

Cilostazol in Parkinson's Disease

Not yet recruiting·—·Phase 2·NCT06612593·50 enrolled

Extremity1 trial

Cilostazol After Lower Extremity Arterial Revascularization Trial

Terminated·WWake Forest University Health Sciences·Phase 4·NCT02374957·20 enrolled

Coronary Artery Disease1 trial

Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease

Unknown status·NNational Cheng-Kung University Hospital·Phase 4·NCT02174939·300 enrolled

Antithrombotic Agents1 trial

OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT01955200·1,724 enrolled

Tics1 trial

Safety and Pharmacokinetics of Probucol and Cilostazol

Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 4·NCT00549978·32 enrolled

Acute1 trial

Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler

Completed·IInje University·Phase 4·NCT00741286·203 enrolled

Cerebral Infarction1 trial

Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.

Completed· Otsuka logo

Otsuka·Phase 3·NCT00766545·1,095 enrolled

Peripheral Vascular Disease1 trial

Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease

Completed·TTungs' Taichung Metroharbour Hospital·Phase 4·NCT00431249·40 enrolled

Aneurysm1 trial

Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm

Completed·SSeoul National University Hospital·Phase 4·NCT03581409·198 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol

Completed·—··NCT05635370·10,398 enrolled

Acute Myocardial Infarction1 trial

Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism

Completed·GGyeongsang National University Hospital·Phase 4·NCT00915733·80 enrolled

Plaque1 trial

Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

Completed·SSeoul National University Bundang Hospital·Phase 3·NCT02266030·100 enrolled

Heart Disease1 trial

Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease

Completed·SSeoul National University Hospital·Phase 4·NCT01291641·342 enrolled

Dementia1 trial

Cilostazol Augmentation Study in Dementia

Completed·SSeoul National University Hospital·Phase 4·NCT01409564·46 enrolled

Genetic Polymorphism1 trial

The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers

Completed·IInje University·N/A·NCT01482117·28 enrolled

Resistance1 trial

Overcome Biochemical Aspirin Resistance Through Cilostazol Combination

Completed·—·Phase 4·NCT00446641·244 enrolled

Platelet Aggregation1 trial

Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

Unknown status·KKangbuk Samsung Hospital·Phase 4·NCT02933788·116 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina

Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 3·NCT02094469·65 enrolled

Cardiovascular Disease1 trial

Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease

Completed·NNational Cheng-Kung University Hospital·Phase 4·NCT02194686·71 enrolled

Neuropathy1 trial

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Recruiting·EEmory University·Phase 2·NCT06492070·70 enrolled

Arterial Stiffness1 trial

Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness

Unknown status·KKorea University Anam Hospital·Phase 4·NCT00573950·48 enrolled

Exercise1 trial

Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)

Unknown status·—·Phase 3·NCT00132743·119 enrolled

Prevention1 trial

Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events

Unknown status·HHanyang University·Phase 4·NCT00886574·400 enrolled

Vascular Dementia1 trial

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

Completed·PPeking University First Hospital·Phase 4·NCT00847860·200 enrolled

Major Depressive Disorder1 trial

The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

Completed·SSadat City University·N/A·NCT04069819·80 enrolled

Cerebral ischemia1 trial

The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients

Completed·—·Phase 4·NCT03116269·80 enrolled

Intermittent Claudication1 trial

Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication

Terminated·GGenovate Biotechnology Co., Ltd.,·Phase 3·NCT06886620·14 enrolled

Fatty Liver Disease1 trial

Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease

Withdrawn·SSadat City University·Phase 1/2·NCT04761848

Osteoarthritis1 trial

The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis

Withdrawn·SSadat City University·Phase 1/2·NCT04789837

Diabetes Mellitus1 trial

Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines

Completed· Otsuka logo

Otsuka·Phase 4·NCT01076478·47 enrolled

Alcoholic Fatty Liver Disease1 trial

Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease

Recruiting·TTanta University·Phase 1/2·NCT07238985·50 enrolled

Complication1 trial

The Efficacy of CILostazol ON Ischemic Complications After DES Implantation

Completed·SSeoul National University Hospital·Phase 4·NCT00776828·960 enrolled

Peripheral Neuropathy1 trial

Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

Completed·MMansoura University·Phase 1/2·NCT05298696·71 enrolled

Diabetic Foot1 trial

Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients

Completed·—·Phase 2/3·NCT06117436·206 enrolled

Tinnitus1 trial

A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus

Completed·JJong Woo Chung·N/A·NCT01378650·50 enrolled

Diabetic Nephropathy1 trial

The Use of Cilostazol in Patients With Diabetic Nephropathy

Completed·—·Phase 4·NCT00272831·62 enrolled

CAR1 trial

Evaluation of Cilostazol in Combination With L-Carnitine

Completed·CColorado Prevention Center·Phase 4·NCT00822172·164 enrolled

Platelet Inhibition1 trial

Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism

Unknown status·GGyeongsang National University Hospital·Phase 3·NCT00891670·80 enrolled

Percutaneous Coronary Intervention1 trial

Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention

Unknown status·SSamsung Medical Center·Phase 4·NCT00938522·400 enrolled

Multiple Sclerosis1 trial

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT03109288·250 enrolled

Unspecified6 trials

Cilostazol Following Peripheral Endovascular Procedures

Unknown status·—·Phase 3·NCT02770274·200 enrolled

Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary

Completed·UUniversity of Southern California·Phase 2·NCT01915069·4 enrolled

Retina is a Marker for Cerebrovascular Heath

Recruiting·MMayo Clinic·Phase 1/2·NCT04753970·100 enrolled

Show 3 more trials

Cilostazol and Endothelial Progenitor Cell

Unknown status·GGyeongsang National University Hospital·Phase 4·NCT04407312·60 enrolled

Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648388·44 enrolled

Pharmacodynamic Study of Cilostazol in Healthy Volunteers

Completed· Otsuka logo

Otsuka·Phase 1·NCT02554721·77 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 15, 1999

PLETAL

NDA NDA020863

Sources

References

[1]
ClinicalTrials.gov — 113 trial records for cilostazol. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Pletal drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — cilostazol compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for cilostazol. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020863). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Phosphodiesterase 3a Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Otsuka

Pletal

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Trials by Indication[1]

Stroke10 trials

Ischemic stroke8 trials

Fasting Conditions6 trials

Headache5 trials

MPA5 trials

Trial4 trials

Atherosclerosis3 trials

Dual Antiplatelet Therapy3 trials

Cognitive impairment2 trials

Cerebral Small Vessel Disease2 trials

Peripheral Arterial Disease2 trials

Clopidogrel2 trials

ART2 trials

Migraine2 trials

Treatment2 trials

Rheumatoid Arthritis2 trials

Interaction2 trials

Subarachnoid Hemorrhage2 trials

TED2 trials

Efficacy and Safety1 trial

Parkinson1 trial

Extremity1 trial

Coronary Artery Disease1 trial

Antithrombotic Agents1 trial

Tics1 trial

Acute1 trial

Cerebral Infarction1 trial

Peripheral Vascular Disease1 trial

Aneurysm1 trial

Drug Repurposing1 trial

Acute Myocardial Infarction1 trial

Plaque1 trial

Heart Disease1 trial

Dementia1 trial

Genetic Polymorphism1 trial

Resistance1 trial

Platelet Aggregation1 trial

Safety and Efficacy1 trial

Cardiovascular Disease1 trial

Neuropathy1 trial

Arterial Stiffness1 trial

Exercise1 trial

Prevention1 trial

Vascular Dementia1 trial

Major Depressive Disorder1 trial

Cerebral ischemia1 trial

Intermittent Claudication1 trial

Fatty Liver Disease1 trial

Osteoarthritis1 trial

Diabetes Mellitus1 trial

Alcoholic Fatty Liver Disease1 trial

Complication1 trial

Peripheral Neuropathy1 trial

Diabetic Foot1 trial

Tinnitus1 trial

Diabetic Nephropathy1 trial

CAR1 trial

Platelet Inhibition1 trial

Percutaneous Coronary Intervention1 trial

Multiple Sclerosis1 trial

Unspecified6 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News